UpdatesPress Release
Windlas Biotech reported record revenue of ₹248 Cr (up 18% YoY). Adjusted EBITDA grew 26% to ₹34 Cr, PAT 37% to ₹25 Cr.
Windlas Biotech LimitedWINDLAS · Filed with the exchange
Company completed a ₹47 Cr share buyback and paid ₹13 Cr dividend for FY26. Plant-6 commercialization is on track.
No comments yet. Be the first.